Normocomplementemic urticarial vasculitis in a young female with persistent joint pain

Emily K Haque¹, Marcus Zaayman², Andrew DeCrescenzo², Alan Menter^{1

2}

Affiliations

Comment

Emily K Haque et al. Int J Dermatol. 2023 Jan.

. 2023 Jan;62(1):e25-e27.

doi: 10.1111/ijd.16025. Epub 2021 Dec 5.

Emily K Haque¹, Marcus Zaayman², Andrew DeCrescenzo², Alan Menter^{1

2}

No abstract available

Comment on

Treatment of urticarial vasculitis: A systematic review.
Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Kolkhir P, et al. J Allergy Clin Immunol. 2019 Feb;143(2):458-466. doi: 10.1016/j.jaci.2018.09.007. Epub 2018 Sep 27. J Allergy Clin Immunol. 2019. PMID: 30268388

1. Kolkhir P, Bonnekoh H, Kocatürk E, et al. Management of urticarial vasculitis: a worldwide physician perspective. World Allergy Organ J 2020; 13: 100107.
1. Kolkhir P, Grakhova M, Bonnekoh H, et al. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol 2019; 143: 458-466.
1. Mehregan DR, Gibson LE. Pathophysiology of urticarial vasculitis. Arch Dermatol 1998; 134: 88-89.
1. Berggren MA, Heinlen L, Isaksson A, et al. EBNA1 expression in a lung transplant recipient with hypocomplementemic urticarial vasculitis syndrome. J Med Virol 2007; 79: 963-969.
1. Chen Y-D, Krause K, Tu P, et al. Response of omalizumab in normocomplementemic urticarial vasculitis. J Allergy Clin Immunol Pract 2020; 8: 2114-2117.